Cost clarity
Readers weighing opioid-addiction program claims can use the material to identify what pricing descriptions do and do not establish.
Plain Compass 58 / About
An independent resource for understanding psychedelic program costs and risks.
Why this exists
Plain Compass 58 exists for adults seeking clear context on ibogaine and 5-MeO-DMT program costs, claims, safeguards, and limitations. The aim is not to promote unapproved treatments, but to make complicated information easier to inspect before someone treats a price, promise, or safety statement as settled fact.
The broader cost-and-risk reference on this site is organized to help readers distinguish what is stated, what is documented, and what remains uncertain. Our resource overview explains the kinds of practical questions the site is designed to help readers frame.
Our editorial approach
We prioritize official records, published literature, registries, and primary-source material where it is available. That approach reflects a simple principle: a claim should be read alongside its source, limits, and relevant context.
For example, clinical-trial records can be checked through the ClinicalTrials.gov registry, while research reporting standards can be considered against guidance from the EQUATOR Network. Neither source makes this resource a provider or an authority; they help establish a more disciplined baseline for assessing information.
Identify the original source behind a price, protocol description, screening statement, or legal claim.
Read claims alongside what is included, excluded, qualified, or left unclear in the available material.
Present the context in plain language without converting uncertainty into a recommendation.
What we cover
The material is organized around recurring questions people encounter when evaluating programs: how pricing is described, which safeguards are claimed, what a reader may need to clarify, and where uncertainty should remain visible. It is not a referral service and does not rank or endorse providers.
Context matters. A reader comparing how ibogaine therapy is described may also need to consider material on retreat cost structures, while a separate review of long-term side-effect considerations can keep financial questions from being treated in isolation.
Who this is for
Plain Compass 58 is for people who want a more deliberate way to read program materials, compare stated inclusions, and recognize the difference between marketing language and independently supported information. The resource is intended to support questions, not replace individual judgment or professional guidance.
Readers weighing opioid-addiction program claims can use the material to identify what pricing descriptions do and do not establish.
Information about reported aftereffects is presented as context for careful questioning, not as individualized guidance.
Coverage touching on depression-related claims and addiction-treatment framing is designed to keep claims legible and bounded.
Independent by design
Signal Ledger is an independent information resource, not a clinic, medical provider, or licensed treatment center. Its content is not medical or legal advice. We do not offer diagnoses, treatment recommendations, or legal determinations.
“Independence means making uncertainty visible, not filling it with assurance.”Our values: independence, cost clarity, risk awareness, plain language, and evidence-first context.